Anticonvulsants Market: By Disease Treatment (Epilepsy, Migraine, Fibromyalgia, Neuropathic pain, Anxiety, Bipolar disorder), By Drugs type(AMPA, Triazine, Benzodiazepine, Dibenzazepine, Others), & Geography-Forecast (2016-2021)
[Lowest Price Guaranteed: $5,250]


Related Topics: Abbott , Epilepsy , Fibromyalgia , GlaxoSmithKline , Novartis , Pfizer , Pharmaceuticals

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Anticonvulsants
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email bioportfolio97@gmail.com.

Introduction

Anticonvulsants (also commonly known as antiepileptic drugs or as antiseizure drugs) are drugs that are used in the prevention or reduction of the severity and frequency of seizures in various types of epilepsy. Epilepsy can be defined as a neurological disorder marked by sudden recurrent episodes of sensory disturbance, loss of consciousness, or convulsions, associated with abnormal electrical activity in the brain. There several different types of anticonvulsants which may act on different receptors in the brain and have different modes of action.

This report identifies the anticonvulsants market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to anticonvulsants market.


Globally North America dominated the market for anticonvulsants in 2015 due to highly developed healthcare infrastructure, high level of awareness, high healthcare spending on epilepsy, and availability of skilled professionals for treating epilepsy. North America was followed by Europe and Asia-Pacific as the second and third largest markets respectively for anticonvulsants in 2015. Demand for anticonvulsants in Asia-Pacific is expected to witness fastest growth in the near future due to constantly increasing medical tourism in the countries such as China, India and Japan. Also increasing investment by the regional governments in the field of medical infrastructure is also expected to result in increased demand for anticonvulsants in the region.

This report on global anticonvulsants is segmented on the basis of various types of anticonvulsants, treated disease and market size in various geographical regions.

On the basis of types of anticonvulsants this report classified as follows covering all major types of anticonvulsants as follows: AMPA, Barbiturate, Benzodiazepine, Carbamate anticonvulsants, Carbonic anhydrase inhibitor, Dibenzazepine, Triazine and Others

On the basis of disease treated, anticonvulsants market is segmented as follows: Epilepsy, Migraine, Fibromyalgia, Neuropathic pain, Anxiety and Bipolar disorder

This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for anticonvulsants in each of the region.

This report identifies all the major companies operating in the global Anticonvulsants market. Some of the major companies’ profiles in detail are as follows:

Pfizer inc.

Novartis International AG

Abbott Laboratories

UCB

Johnson & Johnson

GlaxoSmithKline Pharmaceuticals Ltd

Table of Contents
for Anticonvulsants Market: By Disease Treatment (Epilepsy, Migraine, Fibromyalgia, Neuropathic pain, Anxiety, Bipolar disorder), By Drugs type(AMPA, Triazine, Benzodiazepine, Dibenzazepine, Others), & Geography-Forecast (2016-2021)

  • 1. Anticonvulsants – Market Overview

    2. Executive Summary

    3. Anticonvulsants Market Landscape

    3.1. Market Share Analysis

    3.2. Comparative Analysis

    3.2.1. Product Benchmarking

    3.2.2. End User Profiling

    3.2.3. Top 5 Financials Analysis

    4. Anticonvulsants – Market Forces

    4.1. Drivers

    4.1.1. Increasing global awareness about the availability of anticonvulsants

    4.2. Restraints

    4.2.1. Large scale availability of cost effective generic drugs

    4.3. Opportunities

    4.4. Challenges

    4.5. Porter’s Five Forces Analysis

    4.5.1. Bargaining Power of Suppliers

    4.5.2. Bargaining Power of Buyers

    4.5.3. Threat of New Entrants

    4.5.4. Threat of Substitutes

    4.5.5. Degree of Competition

    5. Anticonvulsants – Strategic Analysis

    5.1. Value Chain Analysis

    5.2. Pricing Analysis

    5.3. Opportunities Analysis

    5.4. Product/Market Life Cycle Analysis

    5.5. Suppliers and Distributors

    6. Global Anticonvulsants Market, By Treatment (2014-2021)

    6.1. Epilepsy

    6.2. Migraine

    6.3. Fibromyalgia

    6.4. Neuropathic pain

    6.5. Anxiety

    6.6. Bipolar disorder

    7. Global Anticonvulsants Market, By Drugs Type (2014-2021)

    7.1. AMPA

    7.2. Barbiturate

    7.3. Benzodiazepine

    7.4. Carbamate anticonvulsants

    7.5. Carbonic anhydrase inhibitor

    7.6. Dibenzazepine

    7.7. Triazine

    7.8. Others

    8. Global Anticonvulsants Market, By Geography (2014-2021)

    8.1. Europe

    8.1.1. Germany

    8.1.2. France

    8.1.3. Italy

    8.1.4. Spain

    8.1.5. Russia

    8.1.6. U.K.

    8.1.7. Rest of Europe

    8.2. Asia Pacific

    8.2.1. China

    8.2.2. India

    8.2.3. Japan

    8.2.4. South Korea

    8.2.5. Rest of Asia-Pacific

    8.3. North America

    8.3.1. U.S.

    8.3.2. Canada

    8.3.3. Mexico

    8.4. Rest of the World (RoW)

    8.4.1. Brazil

    8.4.2. Rest of RoW

    9. Anticonvulsants – Market Entropy

    9.1. Expansion

    9.2. Technological Developments

    9.3. Merger & Acquisitions, and Joint Ventures

    9.4. Supply- Contract

    10. Company Profiles (Top 10 Companies)

    10.1. Pfizer inc.

    10.1.1. Introduction

    10.1.2. Financials

    10.1.3. Key Insights

    10.1.4. Key Strategy

    10.1.5. Product Portfolio

    10.1.6. SWOT Analysis

    10.2. Novartis International AG

    10.2.1. Introduction

    10.2.2. Financials

    10.2.3. Key Insights

    10.2.4. Key Strategy

    10.2.5. Product Portfolio

    10.2.6. SWOT Analysis

    10.3. Abbott Laboratories

    10.3.1. Introduction

    10.3.2. Financials

    10.3.3. Key Insights

    10.3.4. Key Strategy

    10.3.5. Product Portfolio

    10.3.6. SWOT Analysis

    10.4. UCB

    10.4.1. Introduction

    10.4.2. Financials

    10.4.3. Key Insights

    10.4.4. Key Strategy

    10.4.5. Product Portfolio

    10.4.6. SWOT Analysis

    10.5. Johnson & Johnson

    10.5.1. Introduction

    10.5.2. Financials

    10.5.3. Key Insights

    10.5.4. Key Strategy

    10.5.5. Product Portfolio

    10.5.6. SWOT Analysis

    10.6. GlaxoSmithKline Pharmaceuticals Ltd

    10.6.1. Introduction

    10.6.2. Financials

    10.6.3. Key Insights

    10.6.4. Key Strategy

    10.6.5. Product Portfolio

    10.6.6. SWOT Analysis

    10.7. Sunovion Pharmaceuticals, Inc

    10.7.1. Introduction

    10.7.2. Financials

    10.7.3. Key Insights

    10.7.4. Key Strategy

    10.7.5. Product Portfolio

    10.7.6. SWOT Analysis

    10.8. Eisai Pharmaceuticals India Pvt. Ltd

    10.8.1. Introduction

    10.8.2. Financials

    10.8.3. Key Insights

    10.8.4. Key Strategy

    10.8.5. Product Portfolio

    10.8.6. SWOT Analysis

    10.9. Bial

    10.9.1. Introduction

    10.9.2. Financials

    10.9.3. Key Insights

    10.9.4. Key Strategy

    10.9.5. Product Portfolio

    10.9.6. SWOT Analysis

    10.10. Otsuka Pharmaceutical

    10.10.1. Introduction

    10.10.2. Financials

    10.10.3. Key Insights

    10.10.4. Key Strategy

    10.10.5. Product Portfolio

    10.10.6. SWOT Analysis

    *More than 40 Companies are profiled in this Research Report, Complete List available on Request*

    "*Financials would be provided on a best efforts basis for private companies"

    11. Appendix

    11.1. Abbreviations

    11.2. Sources

    11.3. Research Methodology

    11.4. Expert Insights

List Of Tables
in Anticonvulsants Market: By Disease Treatment (Epilepsy, Migraine, Fibromyalgia, Neuropathic pain, Anxiety, Bipolar disorder), By Drugs type(AMPA, Triazine, Benzodiazepine, Dibenzazepine, Others), & Geography-Forecast (2016-2021)

No

Additional Details

Publisher

Publisher Information

Reference

80111 | HCR 0154

Report Format

PDF

 Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Anxiety Disorders Treatment Market, by drug category (SSRIs, TCAs, SNRIs, MAOIs, Anticonvulsants, and Others), therapy (TMS, ECT, CBT, FWS, and Others), and Geography (North America, Europe, Asia Pacific, And Rest Of The World) – Analysis, Share, Trends, Size, & Forecast From 2016 – 2027- COVID- 19 Updated
REPORT HIGHLIGHTThe anxiety disorders & depression treatment market is estimated to represent a glob...
01 Jul 2020 by AnalystView USD $3,250 More Info
Pain Management Drugs Market by Drug Class (NSAIDs, Anesthetics, Anticonvulsants, Antimigraine Agents, Antidepressants, Opioids [Tramadol, Hydrocodone, Oxycodone, and Others], and Nonnarcotic Analgesics) and Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Back Pain, Postoperative Pain, Migraine, and Fibromyalgia) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Pain management is a branch of medicine, which employs approach to ease the suffering and improve th...
01 Oct 2017 by Allied Market Research USD $5,370 More Info
Global Pain Management Drugs Market: Analysis By Type (Opioids, NSAIDs, Anti-Migraine, Anticonvulsants), By Application, By Region, By Country: Opportunities and Forecast (2011-2021)
Executive SummaryA comprehensive research report created through extensive primary research (inputs ...
02 May 2017 by Azoth Analytics USD $2,400 More Info
Diabetic neuropathy Market: By Type (Peripheral Neuropathy, Autonomic Neuropathy); By Treatment Methods (Antidepressants, Anticonvulsants); By Geography (Americas, Europe, Asia-Pacific) – With Forecast (2016-2021)
Neuropathy is defined as the damaged caused to the nerves, and diabetic neuropathy refers to the ner...
26 Feb 2016 by USD $5,250 More Info
Depression Drugs Market: By Medication Class (Monoamine Oxidase Inhibitors (MAOIs), Serotonin-Norepinephrine Reuptake Inhibitors (SNRI), Anticonvulsants, Beta-Blockers, Benzodiazepines, Others); By Brand (Celexa, Zoloft, Cymbalta, Prozac, Paxil, Others)-Forecast (2016-2021)
Depression is a mood disorder that causes relentless feeling of sadness. Many factors causes depress...
25 Feb 2016 by USD $5,250 More Info

We Stock...